Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Nuvation Bio Inc (NYSE: NUVB) closed at $2.75 down -0.36% from its previous closing price of $2.76. In other words, the price has decreased by -$0.36 from its previous closing price. On the day, 4.46 million shares were traded. NUVB stock price reached its highest trading level at $2.865 during the session, while it also had its lowest trading level at $2.72.
Ratios:
For a deeper understanding of Nuvation Bio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.38 and its Current Ratio is at 9.39. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citizens JMP on April 23, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $6.
On March 27, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $1.40 to $10.
BTIG Research Upgraded its Neutral to Buy on March 26, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 18 ’25 when Markel Stacy bought 10,000 shares for $1.71 per share. The transaction valued at 17,100 led to the insider holds 29,591 shares of the business.
Sauvage Philippe bought 4,000 shares of NUVB for $7,160 on Jun 17 ’25. The Chief Financial Officer now owns 9,902 shares after completing the transaction at $1.79 per share. On Jun 16 ’25, another insider, Sauvage Philippe, who serves as the Chief Financial Officer of the company, bought 3,300 shares for $1.83 each. As a result, the insider paid 6,056 and bolstered with 5,902 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUVB now has a Market Capitalization of 941250752 and an Enterprise Value of 391292000. For the stock, the TTM Price-to-Sale (P/S) ratio is 65.74 while its Price-to-Book (P/B) ratio in mrq is 2.49. Its current Enterprise Value per Revenue stands at 27.258 whereas that against EBITDA is 1.942.
Stock Price History:
The Beta on a monthly basis for NUVB is 1.36, which has changed by 0.018518567 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, NUVB has reached a high of $3.45, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 23.16%, while the 200-Day Moving Average is calculated to be 18.69%.
Shares Statistics:
For the past three months, NUVB has traded an average of 6.24M shares per day and 4971040 over the past ten days. A total of 336.84M shares are outstanding, with a floating share count of 230.22M. Insiders hold about 33.54% of the company’s shares, while institutions hold 53.52% stake in the company. Shares short for NUVB as of 1753920000 were 69815687 with a Short Ratio of 11.19, compared to 1751241600 on 65749338. Therefore, it implies a Short% of Shares Outstanding of 69815687 and a Short% of Float of 33.269999999999996.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Nuvation Bio Inc (NUVB) in the stock market.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.13 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.55 and -$0.55 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.52, with 1.0 analysts recommending between -$0.52 and -$0.52.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $7.58M this quarter.It ranges from a high estimate of $11.9M to a low estimate of $4.43M. As of the current estimate, Nuvation Bio Inc’s year-ago sales were $727kFor the next quarter, 5 analysts are estimating revenue of $17.92M. There is a high estimate of $31.5M for the next quarter, whereas the lowest estimate is $8.76M.
A total of 6 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $52.9M, while the lowest revenue estimate was $21.1M, resulting in an average revenue estimate of $36.65M. In the same quarter a year ago, actual revenue was $7.87MBased on 7 analysts’ estimates, the company’s revenue will be $135.18M in the next fiscal year. The high estimate is $209.59M and the low estimate is $79.1M.
